Mounjaro 12.5Mg Kwikpen

Mounjaro KwikPen 12.5mg is an advanced once-weekly injectable device containing Tirzepatide, designed to improve blood sugar control in adults with type 2 diabetes. It also supports weight loss in obese or overweight adults by enhancing insulin sensitivity and reducing appetite.

Key Benefits

• Helps improve blood sugar levels in adults with type 2 diabetes.

• Supports medically supervised weight reduction for obese or overweight patients.

• Easy-to-use injection device suitable for home and clinical environments.

• Enhances insulin sensitivity and reduces appetite for better metabolic control.

Mounjaro KwikPen 12.5mg contains Tirzepatide, a dual GIP and GLP-1 receptor agonist that improves blood sugar control and supports weight reduction. It enhances insulin secretion, slows gastric emptying, and reduces appetite—making it valuable for patients with type 2 diabetes and obesity.

This is a subcutaneous injection (the site of administration for this drug is subcutaneous tissue; it is mostly administered at the abdomen 2 inches away from the belly button, upper arm, or upper thigh). 

Step 1: Locate & clean a 2-inch area around the site with an alcohol swab or pad. 

Step 2: Prepare and unwrap the syringe & make sure the needle is sterile. 

Step 3: Insert the needle into the vein at a 45° angle from the skin. 

Step 4: Withdraw the needle at the same angle & press a cotton ball over the site. 

NOTE: Do not self-administer unless trained by healthcare professionals.

• Not recommended for individuals with medullary thyroid carcinoma or MEN2.

• Avoid use during pregnancy or if planning to conceive.

• Inform your doctor about all ongoing medications to avoid interactions.

• Always store capsules in a cool, dry place away from direct light.